Lassa fever remains a significant public health threat in West Africa, with the World Health Organization estimating 300,000 annual infections and 5,000 deaths—a case fatality rate of 1-2%. In endemic regions such as Sierra Leone and Liberia, infection rates reach 10-16% of the population annually, creating substantial disease burden and healthcare strain.
In response to this critical public health challenge, researchers have developed and tested the LASSARAB vaccine in the first human trial. The phase 1 study demonstrated that the dual rabies-Lassa fever vaccine is both safe and capable of inducing immune responses against both pathogens in healthy adults. These promising results suggest a viable pathway toward widespread vaccination programs that could dramatically reduce Lassa fever mortality and morbidity across affected West African populations. Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Key Finding
📰 Read the full article: First Lassa Fever Vaccine Shows Promise in Early Human Trial →
